Abstract
Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
Keywords: NMDA, glutamate, excitatory aminoacids, bipolar disorder, lithium, neurotransmitter, ionotropic NMDA receptor, schizophrenia, mood disorders, glutamatergic activity
Current Pharmaceutical Design
Title:The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder
Volume: 18 Issue: 12
Author(s): Konstantinos N. Fountoulakis
Affiliation:
Keywords: NMDA, glutamate, excitatory aminoacids, bipolar disorder, lithium, neurotransmitter, ionotropic NMDA receptor, schizophrenia, mood disorders, glutamatergic activity
Abstract: Glutamate is the most abundant excitatory neurotransmitter in the brain and the ionotropic NMDA receptor is one of the major classes of its receptors, thought to play an important role in schizophrenia and mood disorders. The current systematic review summarized the evidence concerning the involvement of NMDA receptors in the pathophysiology of bipolar disorder. Genetic studies point to the genes encoding the NMDA 1, 2A and 2B subunits while neuropathological studies suggest a possible region specific decrease in the density of NMDA receptor and more consistently a reduced NMDA-mediated glutamatergic activity in patients with bipolar disorder in the frame of slower NMDA kinetics because of lower contribution of NR2A subunits. However the literature is poor and incomplete; future research is necessary to elucidate the mechanisms underlying bipolar disorder and its specific relationship to a possible NMDA malfunction and to explore the possibility of developing novel therapeutic agents.
Export Options
About this article
Cite this article as:
Konstantinos N. Fountoulakis , The Possible Involvement of NMDA Glutamate Receptor in the Etiopathogenesis of Bipolar Disorder , Current Pharmaceutical Design 2012; 18 (12) . https://dx.doi.org/10.2174/138161212799958585
DOI https://dx.doi.org/10.2174/138161212799958585 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
Current Alzheimer Research Implications of Epigenetic Mechanisms and their Targets in Cerebral Ischemia Models
Current Neuropharmacology Cancer “Stemness”- Regulating MicroRNAs: Role, Mechanisms and Therapeutic Potential
Current Drug Targets Contribution of Inflammatory Processes to Nerve Cell Toxicity by Bilirubin and Efficacy of Potential Therapeutic Agents
Current Pharmaceutical Design Adult Stem Cell Transplantation in Stroke: Its Limitations and Prospects
Current Stem Cell Research & Therapy Preface
CNS & Neurological Disorders - Drug Targets Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology Recent Advances in Pathophysiology of Traumatic Brain Injury
Current Neuropharmacology The Glutamatergic Neurotransmission in the Central Nervous System
Current Medicinal Chemistry Molecular and Cellular Activities of Vitamin E Analogues
Mini-Reviews in Medicinal Chemistry Biological Rationale for Regular Physical Exercise as an Effective Intervention for the Prevention and Treatment of Depressive Disorders
Current Pharmaceutical Design Neuroprotection by Resveratrol in Diabetic Neuropathy: Concepts & Mechanisms
Current Medicinal Chemistry Multimodality Imaging in Acute Ischemic Stroke
Current Medical Imaging Optical Coherence Tomography Detection of Neurodegeneration in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Current Topics in Medicinal Chemistry Microglia-Neuron Interaction in Inflammatory and Degenerative Diseases: Role of Cholinergic and Noradrenergic Systems
CNS & Neurological Disorders - Drug Targets Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis
Current Medicinal Chemistry Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research PET Imaging in Clinical Drug Abuse Research
Current Pharmaceutical Design Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets